KROS NASDAQ
Keros Therapeutics, Inc.
1W: -2.2%
1M: +1.2%
3M: +3.0%
YTD: -38.7%
1Y: -25.6%
3Y: -64.5%
5Y: -65.6%
$11.36
+0.10 (+0.89%)
Weekly Expected Move ±4.8%
$10
$11
$11
$12
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (62)
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Keros Therapeutics launches $5M share buyback after $20M milestone
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Hsbc Holdings PLC Makes New $761,000 Investment in Keros Therapeutics, Inc. $KROS
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd.
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP
Keros Therapeutics, Inc. $KROS Shares Acquired by Empowered Funds LLC
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Arrowstreet Capital Limited Partnership Sells 744,267 Shares of Keros Therapeutics, Inc. $KROS
New Strong Sell Stocks for July 30th
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $20.40
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Keros Therapeutics GAAP EPS of -$1.21 misses by $0.19, revenue of $0.37M misses by $1.32M
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
KROS Rinvatercept: What to Know Before DMD Phase II Starts
Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of “Hold” from Analysts
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
KROS: Is the Discount Book Value a Value Trap?
KROS Stock: What to Know About Rinvatercept in DMD
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of “Hold” from Analysts
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst
What is HC Wainwright’s Estimate for KROS FY2030 Earnings?
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics: Q4 Earnings Insights
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Is KROS' KER-065 the Next Breakthrough in DMD Space?
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why
Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now?
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc.
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%
Keros Therapeutics Announces Final Results of Tender Offer
Keros Therapeutics Announces Preliminary Results of Tender Offer